Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies

Table 4 Univariate and multivariate analyses of factors affecting long-term virologic response

	Univariate analysis			Multivariate analysis
	RR	95%CI	P value	RR	95%CI	P value
Age (yr)	1.011	0.973-1.050	0.586
Sex (male)	1.156	0.488-2.740	0.741
HBeAg positivity (-)	1.905	0.568-6.383	0.296
Disease status (LC)	0.775	0.293-2.054	0.609
Duration of ETV (mo)	1.077	1.036-1.119	< 0.001	1.022	0.970-1.076	0.419
Serum ALT (IU/L)	1.000	0.998-1.002	0.976
Serum total bilirubin level (mg/dL)	1.405	0.774-2.550	0.264
Serum albumin level (g/dL)	1.214	0.384-3.836	0.741
INR	0.137	0.001-22.543	0.445
Serum HBV DNA level (< 5.2 log10 IU/mL)	5.084	2.231-11.581	< 0.001	2.870	1.049-7.854	0.040
Type of ETV-resistant mutation (rtT184 )	0.780	0.359-1.693	0.529
Presence of IVR-3	8.822	3.228-24.114	< 0.001	4.417	1.402-13.918	0.011
Rescue therapy regimens (ADV/ETV)	2.007	0.928-4.338	0.077	1.678	0.683-4.119	0.259

ADV: Adefovir; ALT: Alanine aminotransferase; CHB: Chronic hepatitis B; ETV: Entecavir; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; INR: International normalized ratio; IVR-3: Initial virologic response at 3 mo; LC: Liver cirrhosis; LMV: Lamivudine.